Esin Izat and Rob Lien on navigating the patient journey to inform commercial operations

An orphan drug manufacturer should follow the patient journey to account for various scenarios in the product's forecast -- from delays in therapy starts to patient compliance and retention. Associate Partner Rob Lien and Manager Esin Izat describe in Pharmaceutical Commerce how detailed analysis and marketing research can help life sciences companies overcome these challenges and contribute to commercial success.